Pharm

Cefepime-Enmetazobactam

search

Cefepime-Enmetazobactam, Cefepime/Enmetazobactam

  • See Also
  1. Cefepime
  • Background
  1. FDA approved in U.S. in 2024
  • Indications
  1. Conditions
    1. Complicated Urinary Tract Infections including Pyelonephritis (FDA approved)
    2. Hospital Acquired Pneumonia (off-label in U.S., approved in Europe)
    3. Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae (ESBL)
      1. Alternative to Carbapenems
  2. Bacteria: Complicated gram-negative infections
    1. Escherichia coli
    2. Klebsiella Pneumoniae
    3. Proteus Mirabilis
    4. Pseudomonas Aeruginosa
    5. Enterobacter cloacae
  • Mechanism
  1. See Cefepime
  • Medications
  1. Cefepime
    1. Fourth Generation Cephalosporin
  2. Enmetazobactam
    1. Beta-Lactamase inhibitor
  • Dosing
  1. Cefepime/Enmetazobactam 2.5 g IV infused over 2 hours every 8 hours for 7-14 days
  2. Renal Dosing
    1. Reduced dose in eGFR <60 ml/min and Hemodialysis
  • Adverse Effects
  1. Elevated Liver Function Tests (including transaminases, Serum Bilirubin)
  2. Headache
  3. Gastrointestinal symptoms (Diarrhea, Nausea, Vomiting)
  4. Neurotoxicity (Seizures, encephalopathy)
    1. Higher risk in renal disease
  5. Nephrotoxicity
    1. Higher risk when combined with Aminoglycosides or Loop Diuretics
  • Drug Interactions
  1. No major CYP450 or P-Glycoprotein transporter interactions
  • Safety
  1. Unknown safety in pregnancy
  2. Unknown safety in Lactation
    1. Low level excretion into Breast Milk
  • References
  1. LoVecchio (2025) Crit Dec Emerg Med 39(8): 42